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Abstract
Previous studies have shown that intrabronchial administration of antibodies (Abs) to MHC class I resulted in development
of obliterative airway disease (OAD), a correlate of chronic human lung allograft rejection. Since development of Abs specific
to mismatched donor HLA class II have also been associated with chronic human lung allograft rejection, we analyzed the
role of Abs to MHC class II in inducing OAD. Administration of MHC class II Abs (M5/114) to C57BL/6 mice induced the
classical features of OAD even though MHC class II expression is absent de novo on murine lung epithelial and endothelial
cells. The induction of OAD was accompanied by enhanced cellular and humoral immune responses to self-antigens
(Collagen V and K- a1Tubulin). Further, lung-infiltrating macrophages demonstrated a switch in their phenotype
predominance from MW1 (F4/80+CD11c+) to MW2 (F4/80+CD206+) following administration of Abs and prior to
development of OAD. Passive administration of macrophages harvested from animals with OAD but not from naı¨ve
animals induced OAD lesions. We conclude that MHC class II Abs induces a phenotype switch of lung infiltrating
macrophages from MW1 (F4/80+CD11c+) to MW2 (F4/80+CD206+) resulting in the breakdown of self-tolerance along with an
increase in autoimmune Th17 response leading to OAD.
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Introduction
Lung transplantation is currently employed as a treatment
option for patients with end-stage pulmonary dysfunction. Chronic
rejection manifested as bronchiolitis obliterans syndrome (BOS)
represents the leading cause of long-term allograft failure in
transplant recipients [1,2]. Multiple immune and nonimmune
mechanisms have been proposed to contribute to the pathogenesis
of chronic rejection resulting in a slow and progressive deteriora-
tion of allograft function over months to years [3,4]. Histopatho-
logically, chronic rejection is an inflammatory process resulting in
replacement of allograft parenchyma with fibroproliferative
changes eventually resulting in occlusion of small airways in the
allograft [5].
Several studies have suggested that allorecognition of mis-
matched donor histocompatibility antigens (HLA) is critical for the
pathogenesis of chronic allograft rejection [6,7]. Clinical and
experimental evidences have documented the role of both T and
B-cell-dependent immune mechanisms for the pathogenesis of
chronic rejection [8,9]. Antibodies (Abs) directed against mis-
matched donor histocompatibility antigens have been shown to
develop during the post-transplant period following kidney, heart,
and lung transplantation and has been shown to correlate with
both acute and chronic rejection [10,11,12]. Allo-Abs can induce
graft injury either directly or indirectly [13]. Specific binding of
the Abs to MHC can result in the activation of lining cells such as
endothelial or epithelial cells leading to the secretion of growth
factors, chemokines, and cytokines which favor the recruitment of
inflammatory cells (macrophages, NK cells and PMNs) to the
graft, contributing to graft damage [14,15,16]. The high levels of
fibrogenic growth factors in the setting of a proinflammatory
microenvironment induces proliferation of fibroblasts and smooth
muscle cells leading to tissue remodeling and subsequent luminal
obliteration of tubular structures in the graft, a hallmark of chronic
rejection [16].
Our studies in lung transplant patients who develop BOS
indicated that the host immune system is primed to recognize both
donor-specific HLA class I and II peptides [17,18]. Moreover, the
development of donor-specific antibodies to HLA demonstrated a
significant correlation with the development of chronic rejection
following human lung transplantation [19]. Studies have also
shown that development of Abs to donor HLA class I precedes the
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development of BOS in human lung transplant recipients [19,20].
In addition to Abs to HLA class I there are reports demonstrating
a significant correlation between the development of Abs to
mismatched donor HLA class II antigens and development of
BOS [21]. These results strongly support the concept that de novo
development of Abs to donor HLA following transplantation can
contribute significantly to the pathogenesis of BOS following
human lung transplantation. Based on this we proposed that Abs
to HLA as well as other risk factors including cellular rejection,
primary graft dysfunction, viral infections and gastroesophageal
reflux, etc can activate inflammatory cascades which will expose
the antigenic epitopes of self-antigens (self-Ags) leading to the
development of an immune response to self-Ags leading to chronic
rejection following lung transplantation [4,22,23,24].
Therefore, with a goal to specifically address the role of
alloimmune responses in the development of OAD, we developed
a murine model for OAD, wherein MHC class I Abs were
intrabronchially administered into mice [25]. In this model, the
animals developed OAD lesions as manifested by epithelial
hyperplasia, cellular infiltration, luminal occlusion and fibrosis
around the smaller bronchioles and developed both cellular and
humoral immune responses to lung associated self-Ags, K-a1
Tubulin (Ka1T) and Collagen V (ColV) [26,27]. However, the
question remained whether Abs to MHC class II can also elicit
OAD lesions since murine endothelial and epithelial cells de novo do
not express MHC class II antigens. In this communication, we
report that intrabronchial administration of Abs to MHC class II
molecules also induced obliterative airway disease (OAD) lesions
in C57bl/6 mice in spite of the fact that murine airway epithelial
and endothelial cells naturally don’t express MHC class II [28].
We demonstrate that resident macrophages play a central role in
the development of MHC class II mediated OAD development as
evidenced by macrophage phenotype shift from MW1 to
autoimmune MW2, along with breakdown of peripheral tolerance
and precipitous increase of Th17 leading to OAD.
Results
Intrabronchial administration of MHC class II Abs induced
the development of OAD lesions
We employed a murine model of OAD, wherein intrabronchial
administration of anti-MHC class I Ab (anti-H2Kb) resulted in the
development of classic OAD lesions in the lungs of C57BL/6 mice
as evidenced cellular infiltration around the vessels, bronchioles,
epithelial hyperplasia and fibrosis [25]. In the current study, we
determined whether administration of MHC class II Abs can also
result in OAD lesions in native lungs since endothelial and
epithelial cells naturally don’t express MHC class II on the cell
surfaces. We administered M5/114, a monoclonal Ab (mAb)
specific to I-A and I-E expressed on C57BL/6 animals or isotype
control Abs (IgG2b) intrabronchially into male C57BL/6 mice (6–
8 weeks old) on days 0,1,2,3, 5 and weekly thereafter. The animals
were sacrificed on day 30 and 60, and lungs were harvested for
histological analysis. As shown in figure 1, morphometric analysis
of sections stained by H&E (Fig. 1A–1F) and trichrome (Fig. 1G–
1L) of the lungs on day 0, 30 and 60 following administration of
anti-MHC class II demonstrated significant luminal occlusion (day
30: Isotype = 1.960.6%; class II = 7.362.1%; day 60: Iso-
type = 2.460.9%; class II = 15.965.2%; p-value,0.05) and
epithelial hyperplasia (day 30: Isotype = 3.160.5%; class
II = 49.1610.7%; day 60: Isotype = 2.960.6%; class
II = 55.2612.3%; p-value,0.05). Similarly, morphometry of
trichrome staining demonstrated significant fibrosis (day 30:
Isotype = 1.760.6%; class II = 17.165.9%; day 60: Iso-
type = 1.660.7%; class II = 41.469.1%; p-value,0.05) in MHC
class II Ab administered animals. Cellular infiltration results
shown in Figure 1M also demonstrated increased cellular
infiltration (day 30: Isotype = 11.964.3%; class II = 59.469.7%;
day 60: Isotype = 16.168.1%; class II = 83.7614.3%; p-va-
lue,0.05). Predominant cellular infiltration was seen around the
bronchioles (day 30: Isotype = 15.765.1%; class II = 52.7611.3%;
day 60: Isotype = 21.969.2%; class II = 86.5613.4%; p-va-
lue,0.05) and blood vessels (day 30: Isotype = 9.663.1%; class
II = 65.9614.4%; day 60: Isotype = 16.364.7%; class
II = 74.7612.9%; p-value,0.05) (Figure 2). Results presented in
figure 2A–D demonstrated that the CD4 T cell infiltration was
markedly increased around the bronchiole (day 30: Iso-
type = 7.962.5%; class II = 23.166.7%; day 60: Iso-
type = 6.761.9%; class II = 35.968.4%; p-value,0.05) and blood
vessels (day 30: Isotype = 6.062.9%; class II = 31.767.9%; day 60:
Isotype = 5.462.1%; class II = 33.664.1%; p-value,0.05) in
MHC class II Ab treated animals. Similarly, an increase in the
CD8 T cell infiltration (Figure 2E–H) around the bronchiole (day
30: Isotype = 2.060.9%; class II = 6.762.6%; day 60: Iso-
type = 1.860.9%; class II = 7.162.3%; p-value,0.05) and blood
vessels (day 30: Isotype = 1.560.9%; class II = 7.962.5%; day 60:
Isotype = 1.760.9%; class II = 8.363.1%; p-value,0.05) was also
noted in MHC class II Ab treated animals. These results
demonstrates that intrabronchial administration of MHC class II
resulted in OAD lesions in the murine model even though the
epithelial and endothelial cells naturally don’t express MHC class
II molecules on the cell surface.
Administration of MHC class II Ab enhances the
development of humoral and cellular responses to lung
associated self-Ags (Ka1T and ColV)
Abs to MHC class I molecule has been shown to induce the
development of immune responses to lung associated self-Ags
mainly ColV and Ka1T both in the murine model of OAD and in
BOS following human lung transplantation [19,25] To determine
if Abs to MHC class II can also induce immune responses to lung
associated self-Ags sera from mice following administration of anti-
MHC class II were tested by ELISA and concentrations of Abs to
ColV and Ka1T were measured on days 7,15,30 and 60. As
shown in figure 3, development of Abs to ColV (day 30:
Isotype = 31619 mg/mL; class II = 94629 mg/mL; day 60: Iso-
type = 37618 mg/mL; class II = 152641 mg/mL; p-value,0.05)
and Ka1T (day 30: Isotype = 23613 mg/mL; class
II = 113632 mg/mL; day 60: Isotype = 25611 mg/mL; class
II = 212646 mg/mL; p-value,0.05) were noted following anti-
MHC class II administration that was significantly increased on
days 30 and 60. This demonstrates induction of immune responses
to self-Ags following administration of MHC class II Ab with the
response on day 60 was equivalent to the MHC class I Ab
treatment of day 30 [25].
To determine the cellular immune responses to ColV and K-
a1T we performed ELISpot on the lung infiltrating lymphocytes.
As shown in figure 4A–B, anti-inflammatory IL-10 specific cellular
response to ColV (day 30: Isotype = 104627 spm; class
II = 43621 spm; day 60: Isotype = 89619 spm; class
II = 30612 spm; p-value,0.05) and Ka1T (day 30: Isoty-
pe = 138626 spm; class II = 73621 spm; day 60: Isoty-
pe = 132630 spm; class II = 51620 spm; p-value,0.05) signifi-
cantly diminished by day 60. On the other hand, pro-
inflammatory IL-17 responses (Figure 4C–D) to ColV (day 30:
Isotype = 362 spm; class II = 97621 spm; day 60: Isoty-
pe = 462 spm; class II = 117611 spm; p-value,0.05) and Ka1T
(day 30: Isotype = 964 spm; class II = 144622 spm; day 60:
Anti-MHC Class II Induced OAD
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Isotype = 1362 spm; class II = 392627 spm; p-value,0.05) sig-
nificantly increased by day 60. Similarly, IFN-c response
(Figure 4E–F) to ColV (day 30: Isotype = 562 spm; class
II = 66613 spm; day 60: Isotype = 762 spm; class
II = 7568 spm; p-value,0.05) and Ka1T (day 30: Isoty-
pe = 561 spm; class II = 156615 spm; day 60: Isoty-
pe = 863 spm; class II = 288640 spm; p-value,0.05) significantly
increased by day 60. This demonstrates that upon intrabronchial
administration of MHC class II Ab induces both Th17 (IL-17) and
Th1 (IFN-c) responses along with a decrease in the Th2/Treg (IL-
10) responses.
Induction of class II expression and activation of
macrophages following intrabronchial administration of
MHC class II Ab
MHC class II molecules are normally not expressed on the
epithelial lining of native murine lungs. To check for the
expression of MHC class II molecules in the lung following
administration of MHC class II Ab, we performed immunofluor-
escence (Figure 5B–E) for MHC class II expression which
demonstrated a 16 fold increase in the epithelial surface expression
of MHC class II by day 60. PCR from the cDNA obtained by
reverse transcription of the mRNA collected from the harvested
lungs on day 0, 15, 30 and 60 also demonstrated increased
expression in the MHC class II molecules (I-Aa) on day 60
compared to day 0 (Figure 5A). We subsequently determined the
role of macrophages in the development of OAD in our murine
model. At first, we determined the macrophage phenotype by
Flow cytometry analysis of lung infiltrating macrophages collected
at day 60 following administration of either anti-MHC class II or
isotype control. Results demonstrated that there is specific shift in
the macrophage phenotype from MW1 (F4/80+ CD11c+) [29] to
MW2 (F4/80+ CD206+) [30] at day 60. As shown in figure 5F, the
M1 phenotype reduced from 91% on day 0 to 37% by day 60
following MHC class II Ab administration. Conversely, the MW2
phenotype increased from 9% on day 0 to 37% on day 60. The
MW2/MW1 ratio (Fig. 5G) increased from 0.09960.005 on day 0
to 1.70360.071 by day 60 (p-value ,0.05). These results strongly
support that following administration of Abs specific to MHC class
II molecules there is specific activation of MW2 macrophages
which we propose to play a role in the development of immune
responses to self-Ags.
Induction of pro-inflammatory chemokines and its
receptors in the lung following administration of Abs to
MHC class II molecule
Gene expression analysis was done for the chemokines and its
receptors. As shown in figure 6A, lungs harvested on day 7
following intrabronchial administration of MHC class II Abs
demonstrated significant increase in the mRNA expression of
CCR5 (8.4 fold), CCR2 (12.7 fold), CX3CR1 (4.5 fold), TARC
(5.7 fold) and MIP-1 (9.4 fold) over isotype treated animals.
Expression of the growth factors (figure 6B), VEGF-A (2.9 fold),
IGF2 (3.4 fold), FGF6 (2.1 fold), NGFb (3.1 fold), BMP6 (1.8 fold)
and BMP8a (4.2 fold) were also significantly increased over isotype
animals. Other CXC and CC chemokines (CXCL13, CCL 2,7,8,
MIP-3 etc) showed only marginal or no increase at all and did not
achieve statistical significance (data not shown).
Figure 1. Histology from lungs harvested on day 0, 30 and 60 following intrabronchial administration of M5/114 (MHC class II Ab)
or LTF-2 (isotype control) to C57BL/6 mice on day 1,2,3,6 and weekly. (A–F) represent lungs analyzed by H&E staining; (G–L) represent lungs
analyzed by trichrome staining; and (M) represents morphometric analysis performed using NIS-Elements BR software to quantitate the epithelial
hyperplasia, cellular infiltration, fibrosis, luminal occlusion and neutrophil infiltration (assayed by myeloperoxidase activity). The data is represented as
a mean 6 SEM over a 5 different animals in each group, the significance (p-value ,0.05) was determined by student-t-test and represented with an
asterisk (*).
doi:10.1371/journal.pone.0042370.g001
Anti-MHC Class II Induced OAD
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Adoptive transfer of macrophages induced OAD lesions
To demonstrate the causal role towards MW2 macrophages in
OAD following MHC class II administration, we performed
adoptive transfer of 16104 and 16105 macrophages (CD11b+)
positively selected from lung infiltrating cells isolated from day 60
following class II Ab administration. Due to the lack of
commercially available F4/80+ purification kit we performed
passive transfer of CD11b+ cells from day 60 MHC class II
antibody treated animals. As shown in figure 6A–D, H&E and
trichrome stain analysis of the lungs harvested on day 30 following
adoptive transfer of macrophages and a single dose of 200 mg/mL
of M5/114 (MHC class II Ab) demonstrated development of OAD
(Figure 7B and D) lesions as evidenced by luminal occlusion,
epithelial hyperplasia, cellular infiltration and fibrosis by day 30
(Figure 7A and C). Similarly, adoptive transfer of day 60
macrophages (MW) also demonstrated increased humoral immune
responses (Figure 7E) to self-Ags ColV (day 30: 16105 MW/single
dose class II Ab = 141635 mg/mL; 16104 MW/single dose class II
Ab = 86618 mg/mL; single dose class II Ab only = 38610 mg/
mL; p-value,0.05) and Ka1T (day 30: 16105 MW/single dose
class II Ab = 193641 mg/mL; 16104 MW/single dose class II
Ab = 107623 mg/mL; single dose class II Ab only = 33612 mg/
mL; p-value,0.05). These results clearly demonstrate that
macrophages of the MW2 phenotype induces immune responses
to self-Ags resulting in OAD lesions following MHC class II Ab
administration in this murine model of OAD.
Figure 2. Immunohistochemistry from lungs harvested on day 30 and 60 following intrabronchial administration of M5/114 (MHC
class II Ab) or LTF-2 (isotype control) to C57BL/6 mice. (A–D) represent staining for CD4+ T cells; (E–H) represent staining for CD8+ T cells; (I
and J) represent morphometric analysis to quantitate the total cellular infiltration, CD8 infiltration, CD4 infiltration on day 15, 30 and 60 around
bronchioles (I) and blood vessels (J). The data is represented as a mean 6 SEM over a 5 different animals in each group, the significance (p-value
,0.05) was determined by student-t-test and represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g002
Figure 3. Analysis of the humoral immune response on serum
collected from day 7, 15, 30 and 60 following administration of
MHC class II Abs or isotype C57BL/6 animals. (A,B) represent the
serum concentration of Abs to self-Ags ColV (A) and Ka1T (B) analyzed
by ELISA. The data is represented as a mean 6 SEM over a 5 different
animals in each group, the significance (p-value,0.05) was determined
by student-t-test and represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g003
Anti-MHC Class II Induced OAD
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e42370
Induction of Th17 differentiation of naı¨ve CD4+ T cells by
lung infiltrating macrophages
The phenotypic switch in the lung infiltrating macrophages is
accompanied by increased Th17 CD4+ T cells specific to ColV
and Ka1T. To determine whether MW2 macrophages were
involved in the Th17 differentiation of the naı¨ve CD4+ T cells we
performed co-culture experiments. The CD11b+ macrophages
were isolated by MACS bead purification from the day 60 lung of
MHC class II Ab administered mice. The PCR performed from
the mRNA extracted from these macrophages demonstrated
(Figure 8A) increased expression of IL-1b, TGF-b, IL-6 and IL-23.
However, the macrophages collected from lung and peritoneum of
isotype administered mice (lane2 and 4) did not show significant
expression of TGF-b and IL-6. We also did not see any IL-17 gene
expression by PCR in the isolated lung infiltrating macrophages
(data not shown). Co-culture of lung infiltrating macrophages with
naı¨ve CD4+ T cells isolated from non-Ab administered naı¨ve wild-
type C57BL/6 mice in the presence of anti-CD3 induced
(Figure 8B) significantly increased the expression of IL-17
compared to macrophages from peritoneum of MHC class II
Ab administered animals as well as from macrophages from lung
and peritoneum of isotype administered animals. Therefore,
activated lung macrophages of MW2 phenotype develop following
intrabronchial MHC class II Ab administration and these
macrophages have the effector function to induce naı¨ve CD4+ T
cells to autoimmune Th17 phenotype.
Discussion
The long term success of human lung transplantation is limited
by the development of chronic rejection predominantly manifested
as BOS that has an incidence as high as 40–70% by 5 years [5]. In
spite of this high incidence, research efforts aimed at discerning the
exact molecular bases of this disease have been limited
predominantly due to the non-availability of an appropriate
animal model [31]. This may be due to many known risk factors
for chronic rejection including surgical trauma, viral infections,
gastroesophageal reflux disease, primary graft dysfunction, alloim-
mune responses, autoimmunity etc [2]. Towards understanding
this complex problem it is postulated that initial pro-inflammatory
microenvironment may lead to the development of alloimmune
responses to donor HLA Ags and breakdown of peripheral
tolerance and development of immune responses to self-Ags
(mainly ColV and Ka1T) culminating in a fibrotic cascaded
leading to chronic lung allograft rejection [4,23,24]. Despite
limitations of current animal models including heterotopic tracheal
transplant model [32], murine orthotopic vascularized lung
transplant model [33] and minor mismatch lung transplant model
[34] there have been significant development in our understanding
of the molecular and genetic basis of chronic lung allograft
rejection. With a primary emphasis to study the role of
alloimmunity in the development of autoimmune responses and
histologic development of features of chronic lung allograft
Figure 4. Analysis of the cellular immune response on lung infiltrating lymphocytes collected on day 7, 15, 30 and 60 following
administration of MHC class II Abs or isotype C57BL/6 animals, analyzed by ELISpot. (A,B) represent the ColV (A) and Ka1T (B) specific IL-
10 responses; (C,D) represent the ColV (C) and Ka1T (D) specific IL-17 responses; (E, F) represent the ColV (E) and Ka1T (F) specific IFN-c responses. The
data is represented as a mean6 SEM over a 5 different animals in each group, the significance (p-value,0.05) was determined by student-t-test and
represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g004
Anti-MHC Class II Induced OAD
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rejection, we developed a murine model [25] wherein Abs to
MHC class I molecules were administered intrabronchially and
upon specific binding of these Abs to lung epithelium resulted in
the breakdown of peripheral tolerance to self-Ags and induced
OAD (fibrosis, epithelial hyperplasia, cellular infiltration and
luminal occlusion), which are considered the cardinal features of
chronic lung allograft rejection. In spite of the absence of lung
transplantation and non-physiologic administration of MHC class
I Abs intrabronchially the ability of this model to replicate the
features of chronic lung allograft rejection makes it a viable model
to study the alloimmune induced autoimmunity following lung
transplantation. Previous studies have demonstrated that following
Figure 5. Analysis of the MHC class II expression and macrophage phenotype prior to and following the administration of MHC
class II Abs. (A) represent MHC class II (I-Aka) expression in the lung analyzed by PCR on day 0, 15, 30 and 60 following the administration of M5/114;
(B–D) represent the immunohistochemistry on harvested lungs with MHC class II staining prior to administration of MHC class II Ab (B), day 60 of
isotype administration (C) and day 60 of MHC class II Ab administration; (E) represent the morphometric quantitation of the MHC class II expression in
the lung on day 0, 30 and 60 following the administration of MHC class II Ab or isotype Ab; (F, G) represent the phenotype of the lung infiltration
macrophages following administration of MHC class II Ab analyzed by flow cytometry, green represent F4/80 staining (MW), orange represent CD11c
staining (MW1), and red represent CD206 staining (MW2); and (G) represent the ratio of MW2 to MW1 macrophage phenotype on day 0, 7, 15, 30 and
60. The data is represented as a mean6 SEM over a 5 different animals in each group, the significance (p-value,0.05) was determined by student-t-
test and represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g005
Figure 6. Gene expression analysis of the chemokines, their receptors and growth factors on the on the mRNA collected from the
lungs harvested on day 7. The data is represented as a mean 6 SEM over a 5 different animals in each group.
doi:10.1371/journal.pone.0042370.g006
Anti-MHC Class II Induced OAD
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human lung transplantation Abs to HLA class I and II develop
and are strongly correlated with the development of BOS. HLA
class II unlike class I antigens have limited cell surface expression
and are selectively expressed on macrophages, B-cells and
dendritic cells. Native murine lung epithelium does not have
expression of MHC class II molecules. However, MHC class II
molecules are expressed on the alveolar macrophages [28].
In this communication, we analyzed the pathophysiological
mechanisms by which Abs to MHC class II lead to the
development of OAD. Following initial pilot studies with various
concentrations of MHC class II antibodies (50–300 mg) we have
decided to use 200 mg in 70 mL of PBS solution. We demonstrate
that intrabronchial application of MHC class II Abs caused
development of classic histologic features of OAD by day 60
(Figure 1 and 2). However, the development of OAD with MHC
class II Abs (60 days) was delayed as compared to MHC class I Abs
which occurs prior to 30 days. Similar to class I Abs, class II Abs
also induced cellular immune responses to self-Ags by activation of
Th17 responses and humoral immune responses to self-Ags ColV
and Ka1T along with a concomitant decrease in the protective
anti-inflammatory IL-10 response (Figure 3 and 4). This data is in
line with previous findings in human and animal studies that
towards the development of cellular mediated autoimmune
responses to self-Ags there is shift in immune responses from
protective IL-10 to potential lethal IFN-c and IL-17 [22,25,26,35].
This raised an interesting question as to what is the cell type to
which MHC class II Abs bind to resulting in their possible
activation. As shown in figure 5A, mRNA analysis demonstrated
that native lung as expected had minimal expression of MHC class
II molecules. However, following administration of class II Abs, by
day 30 there is increased expression of MHC class II molecule in
the murine lung. Furthermore, the alveolar macrophages which
have intrinsic expression of MHC class II molecule undergo a
phenotype switch to MW2 (CD206+) (Fig. 5B–5C), which has been
attributed to be involved in the development of autoimmune
responses. A convincing evidence towards the role of MW2
macrophages in experimental autoimmune encephalitis (EAE) has
already been demonstrated wherein the macrophage/microglial
cells isolated from CNS with EAE demonstrated MW2 phenotype
[36]. Similarly, gene expression profile of peripheral blood cells
from patients with new-onset systemic juvenile idiopathic arthritis
revealed that the patients with this disease have increased markers
of MW2 phenotype [37]. Additionally, around 30% of macro-
phages isolated from murine model for autoimmune myocarditis
showed MW2 phenotype [38]. Our data is in agreement with the
above mentioned studies wherein administration of MHC class II
Abs induced activation of macrophages to autoimmune MW2
phenotype [38]. We also performed passive intrabronchial
adoptive transfer of MW2 macrophages harvested from 60 days
following anti-MHC class II administration induced OAD in naı¨ve
animals. Future studies with clodronate administration to
specifically deplete macrophages would be needed to confirm
our current data. The gene expression profile also demonstrated
upregulation of macrophage specific chemokines, CCR5, CCR2,
CX3CR1 [39,40,41]. Taken together these experiments estab-
lishes an obligatory role for macrophage activation and phenotype
switch to MW2 phenotype in the development of MHC class II Ab
induced OAD. The MHC class II knock out animals, although
would specifically prove the requirement of the ligation of the
MHC class II antibody to the MHC class II molecule, this
however will lack the entire class II antigen presentation pathway,
and consequently will not account for the other variables such as
induction of IL-17/CD4+T cells, IL-6 and pro-inflammatory
cytokine induced IL-17 signaling, which is one of the key factors in
the development of OAD. Previous studies in our laboratory [25]
using anti-keratin antibody and current studies with LTF-2
antibody (IgG2b isotype control) did not cause development of
OAD lesions. These results support that specific ligation by the
Fab2 fragment to the MHC molecules are needed and Fc signaling
by itself may not be sufficient. However, studies with the specific
Fab2 fragment of the antibodies and/or use of FccRIIb knock out
mice need to be performed to rule out the role of Fc signaling and
its impact on OAD induced by anti-MHC class II.
To demonstrate for the effector role of activated MW phenotype
in conjunction with specific antigen stimulation, we performed co-
culture experiments with naı¨ve CD4+ T-cells in the presence of
lung infiltrating MW (Figure 8). This resulted in the differentiation
of naı¨ve CD4+T cells to IL-17 secreting T cells. In contrast,
peritoneal macrophages from class II Ab administered animals
and naı¨ve macrophages from wild type both from lung and
peritoneum did not induce significant Th17 differentiation. The
ability of local Ag presenting cells to induce Th17 cells may
therefore be an initial early stimulus in addition to the local
cytokine expression and inflammatory milieu. Recent studies have
demonstrated that activated lamina propria macrophages in GI
tract induce Th17 CD4+T cell phenotype [42]. Similarly, IL-6
expressing dendritic cells in EAE model have been shown to
induce the polarization of Th17 cells from naı¨ve CD4 T cell
precursor phenotype [43]. These data are also in agreement with
our findings that activation of macrophages to MW2 phenotype
has the ability to induce autoimmune Th17 CD4+ T cells, which
Figure 7. Histology from lungs harvested on day 30 following
adoptive transfer of day 60 macrophages isolated at day 60
from MHC class II Ab administered mice. 0.1, and 16105 CD11b+
macrophages intrabronchially, and single intrabronchial administration
of MHC class II Ab was done for adoptive transfer experiments. (A, B)
H&E staining of the lungs collected from day 30 without (A) and with (B)
adoptive transfer of 16105 CD11b+ macrophages following single
administration of MHC class II Ab. (C, D) Trichrome staining of the lungs
collected from day 30 without (C) and with (D) adoptive transfer of
16105 CD11b+ macrophages following single administration of MHC
class II Ab; and (E) serum concentration of Abs to self-Ags ColV and
Ka1T analyzed by ELISA. The data is represented as a mean 6 SEM over
a 5 different animals in each group, the significance (p-value,0.05) was
determined by student-t-test and represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g007
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we consider as the initial event leading to the development of
OAD lesions.
There is also strong evidence for autoreactivity to Ka1T and
ColV in the pathogenesis of chronic rejection following human
lung transplant [19,22] and in animal models of lung allograft
rejection [25,44]. Studies analyzing the immune responses to self-
Ags following transplantation have clearly demonstrated that the
indirect allorecognition pathway plays a crucial role [45]. In this
study, analysis of the cells infiltrating the lung indicates that they
are activated and secrete IFN-c and IL-17, along with a decrease
in IL-10 specific to Ka1T and ColV (Figure 4). This was followed
by the development of Abs to both of these auto-Ags. It is also of
interest to note that cells infiltrating the lung produced large
amounts of IL-17 following stimulation with both Ka1T and ColV
(Figure 3). IL-17 has been shown to be a potent proinflammatory
cytokine to the local tissue environment leading to a strong
proinflammatory signal that results in enhanced autoimmune
response [46]. IL-17 has also been shown to play a crucial role in
the induction of humoral autoimmune responses [47]. Analysis of
the cellular responses to ColV in lung transplant recipients has
been shown to be dependent on CD4 T cells and monocytes [35].
This response was found to be dependent on IL-6, IL-23, IL-1b,
TGF-b and IL-17. The risk of BOS development was observed to
correlate with the severity of the self-Ag-specific T cell responses
[35]. Furthermore, in this study we demonstrate that the
interaction between macrophages and IL-17 is crucial in induction
of the autoimmune responses. Studies have also demonstrated that
a deficiency in the IL-17 or blocking of IL-17 results in a decrease
in the production of auto-Abs [48,49]. Therefore, our finding of
IL-17-producing T cells following stimulation with self-Ags
indicates that these T cells provide signals toward activation of B
cells, resulting in Abs to self-Ags, such as Ka1T and ColV. These
results are in agreement with the report that in IL-17-deficient
mice have reduced capacity to induce autoimmunity and results in
lack of formation of germinal centers leading to a reduction in the
titer of auto-Abs [50]. Hence, we propose that macrophage
induced IL-17/Th17 polarization is a critical mediator in the
induction of autoimmunity following administration of the anti-
MHC class II Abs, resulting in the development of chronic
rejection following lung transplant. This is in line with our
previous studies on anti-MHC class I induced OAD model, where
in administration of ACE inhibitors and ARBs which modulate
rennin angiotensin aldosterone system (RAAS) have been shown
to downregulate IL-17 signaling through tumor necrosis factor-a-
dependant IL-6 and through p38/MAPKinase pathways leading
to abrogation of anti-MHC-induced OAD [51]. Further, although
the exact mechanisms are not clear, recent randomized control
trail by Vos et al, have demonstrated that azithromycin can
prevent the incidence of chronic rejection in human lung
transplant recipients [52]. However the comprehensive analysis
of MW2 signaling pathways leading to autoimmune responses and
role of various drugs in abrogation of these changes leading to
Figure 8. Induction of Th17 cell from naı¨ve T cells by lung infiltrating macrophages. (A) Flow cytometry analysis for the expression of IL-
1b, TGF-b, IL-6 and IL-23 cytokines on CD4+gated population; (B) gene expression of IL-1b, TGF-b, IL-6 and IL-23 in macrophages collected from lungs;
(lane1) and peritoneum (lane 3) day 60 MHC class II Ab administered mice, lane 2 and 4 represent macrophages collected from lung and peritoneum
of isotype administered animals. (B) represent IL-17 concentration from the media collected by co-culture of 1:1 ratio of naı¨ve T cells collected from
splenocytes of wild type C57BL/6 mice and cultured with macrophages collected from lung (1) and peritoneum (3) of day 60 MHC class II Ab
administerd mice, 2 and 4 represent co culture with macrophages collected from lung (2) and peritoneum (4) of day 60 Isotype Ab administered
mice, (5 in panel B) represent lung infiltrating macrophages of day 60 MHC class II Ab administered mice in the absence of naı¨ve T cells. The data is
represented as a mean6 SEM over a 5 different experiments, the cohort with significant expression of IL-17 (p-value,0.005) compared to isotype Ab
administered group (5) were represented with an asterisk (*).
doi:10.1371/journal.pone.0042370.g008
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prevention of chronic rejection following lung transplantation
needs further investigation.
In conclusion, our report demonstrates that MHC class II Abs
induce OAD in a murine model for chronic lung allograft
rejection. The development of OAD was strongly associated with
macrophage activation to autoimmune MW2 phenotype. Based on
this, we conclude that ligation of class II molecules expressed on
alveolar macrophages by its specific Abs promote pro-inflamma-
tory microenvironment leading to development of Th17 mediated
immune responses to self-Ags leading to fibrosis and OAD
resulting in chronic allograft dysfunction. Novel therapeutic
strategies aimed at modifying or inhibiting the macrophage
activation could aid in the prevention of development of chronic
rejection following human lung transplantation.
Materials and Methods
Animal Studies
We utilized a murine model in which OAD, correlate of BOS,
chronic rejection, was induced in the distal airways following
ligation of MHC molecules in the lung by a mAb to MHC class I
Ags [25]. All experiments were performed in compliance with the
guidelines of the Institutional Laboratory Animal Care and Use
Committee of Washington University School of Medicine
(protocol 20070121). Murine mAb M5/114 specific to MHC
class II Ags (both I-A and I-E, IgG2b) and isotype control LTF-2
were administered into male C57BL/6 (6–8 wk old) which has no
detectable endotoxin as measured by Limulus amebocyte lysate
assay. Abs were given at a dose of 200 mg/administration into
mice. Intrabronchial administration was done as follows: each
mouse was anesthetized, and the tongue was pulled out. A
mosquito clamp was inserted into the mouth, and a 20-gauge
catheter was placed into the trachea. The MHC class II Ab, M5/
114 (200 mg) or the isotype control LTF-2 was administered into
the lung on days 1, 2, 3, and 6, and then weekly thereafter.
Histology and morphometric analysis of cellular
infiltration, fibrosis and luminal occlusion
Lungs were fixed in 10% formaldehyde. Sections were cut at
5 mm thickness and stained with H&E and Masson’s trichrome
and analyzed under microscope Nikon ECLIPSE 55i (Melville,
NY) using NIS-Elements BR software (Melville, NY). Specific
CD4 and CD8 infiltration was analyzed on frozen sections treated
with 3% H2O2 and EtOH for 10 min to block endogenous
peroxidase activity. The sections were blocked with biotin/Avidin
blocking reagent (Avidin/Biotin Blocking Kit, Vector Labora-
tories, Butlinghame, CA). Primary Abs were diluted using Ab
dilution solution (BD Bioscienes, San Jose, CA). The sections were
incubated with purified rat anti-mouse CD4 and CD8 (5 mg/mL,
Santa Cruz Biotech, Santa Cruz, CA). The sections were then
treated with appropriate biotin conjugated secondary Abs followed
by streptavidin-HRP. The presence of positive cells was deter-
mined with diaminobenzidine substrate kit (BD Phamingen,
SanDeigo, CA). Immunohistochemistry for MHC class II expres-
sion was performed using directly FITC conjugated MHC class II
antibody (eBiosciences, San Diago, CA). Percentage of cellular
infiltration, luminal occlusion and fibrosis was morphometrically
calculated using NIS-Elements BR software (Melville, NY).
Percentage of fibrosis was quantified morphometrically by
addition of the total area enclosed by basement membrane at 5
different high power (406) field and dividing by a factor of 5.
Percentage of cellular infiltration and epithelial abnormalities was
calculated at 5 different high power fields (406), respectively.
Slides were analyzed by random sampling after individually
analyzed by two blinded professionals. The data is represented as a
mean 6 SEM over a 5 different measurements.
ELISpot assay
ELISpot assays were performed on CD4+ lung infiltrating
lymphocytes, as described previously [53]. Briefly, MultiScreen
96-well filtration plates (Millipore, Billerica, MA) were coated
overnight at 4uC with 5.0 mg/ml capture mouse cytokine-specific
mAb (BD Biosciences, San Diego, CA) in 0.05 M carbonate-
bicarbonate buffer (pH 9.6). The plates were blocked with 5%
BSA for 2 hrs and washed three times with PBS. Subsequently,
36105 CD4+ T cells collected from the lung by positive selction on
MACS magnetic beads (Militenyi Biotec, Auburn, CA) were
cultured in triplicate in the presence of ColV (20 mg/mL, BD
Biosciences, San Diego, CA) or human Ka1T (10 mg/mL, from
recombinant expression vectors in our laboratory) and irradiated
feeder autologous splenocytes (1:1 ratio). After 48–72 hrs, the
plates were washed three times with PBS and three times with
0.05% PBS/Tween 20. Then, 2.0 mg/ml biotinylated mouse
cytokine-specific mAb (BD Biosciences, San Diego, CA) in PBS/
BSA/Tween 20 was added to the wells. After an O/N incubation
at 4uC, the plates were washed three times, and HRP-labeled
streptavidin (BD Biosciences, San Diego, CA) diluted 1/100 in
PBS/BSA/Tween 20 was added to the wells. After 2 hrs, the
plates were developed and spots were analyzed by ImmunoSpot
Series I analyzer (Cellular Technology, Shaker Heights, OH). The
results were expressed as spots per million cells 6 SE. Any spots
obtained by culturing T cell lines with antigen presenting cells
alone without ColV or human Ka1T were subtracted from the
number of spots in the test cultures.
Myeloperoxidase (MPO) Assay
Extracts were prepared by sonication of 100 mg of lungs
harvested on days 15 and 30. Neutrophil activity was determined
by MPO assay as described earlier [54]. The data was represented
as mean 6SEM for 5 different measurements.
ELISA
ELISA plates (Nunc, Rochester, NY) were coated with ColV or
Ka1T (1 mg/ml) in PBS overnight at 4uC [54]. Serum samples
were collected from mice treated with anti-MHC class II Ab or
isotype Ab. Serum samples were tested (1:250 and 1:500) for
binding to ColV. Detection was done with anti-mouse IgG, IgM-
HRP (Santa Cruz Biotechnology, Santa Cruz, CA), and develop-
ment using tetramethylbenzidine substrate and read at 450 nm. A
sample was considered as positive if the values were over an
average cutoff values obtained from normal sera from 10 different
mice. Concentration of Abs was calculated based on a standard
curve using the binding of known concentration of anti-ColV Abs
(Santa Cruz Biotechnology, Santa Cruz, CA).
Gene expression assay
The PCR was performed to determine gene expression of MHC
class II molecule and other interleukins by reverse transcription of
mRNA obtained from harvested lungs. Total RNA was extracted
from 0.5 mg of lung using TRIzol reagent (Sigma–Aldrich, St
Louis, MO). RNA samples were quantified by absorbance at
260 nm. The RNA was reverse-transcribed and PCR was
performed in a final reaction volume of 50 mL. Primers used
were: I-Aa forward, 59-AAATCCACCCCAGCTACCAAT-39, I-
Aa reverse, 59-GCTGACCCAGCAGCACAG-39 [55]; 18S rRNA
forward, 59-CTTAAAGGAATTGACGGAAG-39 and reverse, 59-
TCCGCAGGTTCACCTACGGA-39; b-actin forward, 59-
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ATCGTGCGTGACATCAAAGAGA-39 and reverse, 59 -CCA-
CAGGATTCCATACCCAAGA-39; TGF-b forward, 59-
GATCCCCCTAGCCTCTCATC-39 and reverse, 59-GCA-
CAAGCAGGATTGAGTGA-39; IL-6 forward, 59-
AGTTGCCTTCTTGGGACT-GA-39 and reverse, 59-CA-
GAATTGCCATTGCACAAC-39; IL-1b forward, 59-AAACA-
GATGAAGTGCTCCTTCCAGG- 39 and reverse, 59TGGA-
GAACACCACTTGTTGCTCCA- 39 and IL-23p19: primers 59-
AGCGGGACATATGAATCTACTAAGAGA-39, 59-
GTCCTAGTAGGGAGGTGTGAAGTTG-39. The growth fac-
tor expression was analyzed by growth factor RT2-PCR
profilerTM (SA Biosciences, Frederick, MD). Each sample was
analyzed in triplicate. Cycling conditions consisted of an initial
denaturation of 95uC for 15 min, followed by 40 cycles of 95uC for
30 s, followed by 61uC for 1 min.
Flow cytometry
Expression of individual cell specific markers proteins was
analyzed by flow cytometry. Splenocytes and lung infiltrating cells
were collected by collagen digestion of harvested spleen and lungs,
respectively. The specific cellular infiltration was quantitated using
appropriate fluorescent tagged Abs for CD4, CD11c, F4/80,
CD206, IL-1b, TGF-b, IL-6 and IL-23 (Santa Cruz Biotech, CA),
was performed prior to treatment with primary Abs, and then by
fluorescent tagged secondary Ab as per manufacturer’s protocol
(BD Biosciences, Sparks, MD). Cells were analyzed on a LSRII
flow cytometer (BD Biosciences) using FACSDiva software. All
measurements were taken for 5,000 events that are a display of
relative cell count. The data was represented as a mean 6 SEM
over a 5 different measurements.
Adoptive transfer
To determine the role of macrophages in induction of OAD
following ligation of anti-MHC class II, we administered two
concentrations of (16105 or 16104) of CD11b+ macrophages.
These cell populations were positively selected from lung
infiltrating cells [56] at day 60 from mice which were administered
with MHC class II Abs or control Abs. The cells were
intrabronchially administered along with a single dose of MHC
class II Ab since it is our contention that some inflammatory event
such as that induced by administration of Abs has to be present for
the initiation of immune responses leading to immune response to
self-Ags. In previous experiments single dose of Ab either anti-
MHC class I or II did not induce OAD lesions. Therefore, if OAD
lesions were noted following the above mentioned protocol it can
be attributed to adoptively transferred cell population. Serum from
these mice was collected on day 30 to quantitate the levels of Abs
against ColV and Ka1T, as described earlier. Histopathological
analysis of the lungs was also performed to determine the levels of
cellular infiltration and epithelial hyperplasia by H&E staining.
Fibrosis in the lungs was analyzed by trichrome staining.
Statistical analysis
Morphometric analysis on tissue sections was performed using
NIS-Elements BR software (Melville, NY). The statistical analysis
is performed either using GraphPad5.0 (LaJolla, CA) or Origin 6.0
(Northampton, MA) and all the data is represented as a mean 6
SEM over a 5 different measurements. The significance was
established by performing student-t-test and considered significant
when p-value was determined to be less than 0.05.
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